Jonathan Moreira

Dr. Jonathan Moreira serves as Associate Professor of Medicine in the Department of Medicine, Division of Hematology/Oncology at Northwestern University's Feinberg School of Medicine. His clinical expertise centers on hematopoietic stem cell transplantation for hematologic malignancies and solid tumors, with additional focus on lymphoid malignancies and graft vs. host disease management.

Education:

• BS: University of Illinois at Urbana-Champaign (2005)
• BA: University of Illinois at Urbana-Champaign (2005)
• MD: Loyola University/Stritch School of Medicine (2009)
• Residency: Mayo Medical School, Internal Medicine (2012)
• Fellowship: Northwestern University, McGaw Medical Center, Hematology-Oncology (2016)

Dr. Moreira's research integrates translational oncology with health equity initiatives. His primary focus involves optimizing stem cell transplant protocols through novel therapeutic agents and microbiome research, while rigorously examining socioeconomic and racial disparities in cancer outcomes. Current investigations explore how neighborhood characteristics and dietary patterns influence microbiome evolution during transplantation—a pioneering approach linking social determinants to biological mechanisms in hematologic malignancies.

His recent publications reveal two dominant research trajectories: 1) Advancements in CAR-T cell therapy for aggressive lymphomas including double-hit variants, utilizing multicenter real-world data analysis; 2) Quantification of racial/socioeconomic disparities in stem cell transplant survival through large cohort studies. These efforts consistently emphasize practical clinical applications and equitable access to emerging therapies.

Scientific Recognition:

• Castle Connolly Top Doctor Award (2023)
• NU-LEAP Leadership Program (2021)
• ASH Advocacy Leadership Institute (2019)
• National Hispanic Medical Association Young Physician of the Year (2019)
• Negocios Now Who's Who in Hispanic Chicago (2018)

Dr. Moreira leads active clinical trials including a geographic microbiome study examining socioeconomic influences on transplantation outcomes (IRB STU00213358) and a Phase 3 trial of ITK inhibitor soquelitinib for T-cell lymphomas (NCT06561048). His professional service spans the National Comprehensive Cancer Network, Radiation Injury Treatment Network, and multiple oncology societies including ASH and ASCT. While specific advising details aren't documented, his academic rank indicates mentorship of hematology/oncology trainees within Northwestern's fellowship programs.

His professional affiliations demonstrate commitment to underserved populations: Medical Organization for Latino Advancement membership since 2017 and leadership in health equity research examining neighborhood effects on transplantation outcomes through microbiome analysis.